Prolia (Denosumab) Side Effects: Withdrawal and Discontinuation Syndrome Explained

What Is Denosumab Withdrawal Syndrome?

Denosumab withdrawal syndrome describes the rebound increase in bone resorption and fracture risk that follows the cessation of Prolia. Because denosumab suppresses the RANK ligand (RANKL) pathway reversibly, osteoclast activity surges back when drug levels fall. That surge is sharper and faster than the bone loss seen when bisphosphonates are stopped, because bisphosphonates remain embedded in bone matrix for years after the last dose while denosumab clears from the body within weeks.

The phenomenon was first described systematically by Cummings et al. After the FREEDOM extension trial, where participants who stopped denosumab lost bone at a rate faster than expected and had a higher vertebral fracture incidence than those who had never received treatment. [1]

Why Denosumab Is Different From Bisphosphonates

Bisphosphonates bind hydroxyapatite. They stay in bone tissue long after patients stop taking them, providing a residual antiresorptive effect that can last 2 to 5 years. Denosumab does not bind bone. Its half-life is roughly 26 days, and its pharmacodynamic effect on bone turnover markers vanishes almost completely by month 5 to 6 post-injection. [2] This means there is no residual drug activity to cushion the rebound.

The RANKL Rebound Mechanism

When denosumab is present, RANKL cannot bind RANK receptors on osteoclast precursors. Osteoclast formation is suppressed. When the drug is withdrawn, accumulated RANKL floods unblocked RANK receptors, triggering a wave of new osteoclast maturation. Bone resorption markers, specifically serum C-terminal telopeptide (CTX), spike to levels above pre-treatment baseline within 3 months of the last dose. [3] That overshoot in resorption drives the disproportionate bone loss.

How Common Are Multiple Vertebral Fractures After Stopping Prolia?

Multiple vertebral fractures (MVFs) after denosumab discontinuation are well-documented and occur at a rate that exceeds background population risk. A 2017 retrospective analysis by Cummings and colleagues identified 16 patients who developed 3 or more vertebral fractures within 8 to 16 months of stopping denosumab. [1] A subsequent systematic review published in Osteoporosis International (2020) pooled data from observational studies and found MVF rates of approximately 3.4% in patients who discontinued without bridging therapy, compared to 1.1% in those who transitioned to bisphosphonates. [4]

The fractures are not trivial. They often occur at multiple spinal levels simultaneously, producing acute pain, height loss, and kyphosis that can be irreversible. Several case series report fractures at 4 to 7 vertebral levels in a single patient within one year of stopping.

Risk Factors That Amplify Rebound Fracture Likelihood

Not every patient who stops denosumab fractures. The risk is concentrated in people with these characteristics:

• Longer duration of denosumab therapy (more than 3 years of injections)
• Prevalent vertebral fractures before or during treatment
• Low BMD at baseline (T-score below -2.5 at lumbar spine or femoral neck)
• Prior glucocorticoid use
• Stopping denosumab due to a missed injection rather than a planned transition

A 2021 analysis in the Journal of Bone and Mineral Research found that patients with a prior vertebral fracture had a hazard ratio of 3.2 for MVF after discontinuation versus those without. [5] Age above 70 and femoral neck T-score below -2.0 were also independent predictors.

How Quickly Does the Risk Emerge?

The fracture window opens faster than most patients or prescribers expect. Bone turnover markers begin rising within 1 to 3 months of the missed injection. BMD decline becomes measurable on DXA by month 6. Fractures in published case reports cluster at 7 to 18 months after the last dose, with the peak at roughly 9 to 12 months. [4] A patient who simply does not return for their 6-month injection is already at risk before anyone realizes treatment has lapsed.

General Adverse Events of Prolia Beyond Withdrawal

Denosumab carries several adverse effects unrelated to discontinuation. Understanding the full safety profile matters for prescribing decisions.

Hypocalcemia

Hypocalcemia is the most immediately dangerous on-therapy adverse event. Denosumab suppresses bone resorption, which reduces calcium flux from bone into serum. Pre-existing vitamin D deficiency amplifies the drop. The prescribing information requires that serum calcium be corrected before starting denosumab, and that patients receive at least 1,000 mg calcium and 400 IU vitamin D daily. [6] Severe symptomatic hypocalcemia, including tetany and prolonged QT, has been reported in post-market data, particularly in patients with chronic kidney disease stage 3 to 5. [7]

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) occurs at a lower incidence with the osteoporosis dose (60 mg every 6 months) than with the oncology dose (Xgeva, 120 mg monthly). A large pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) through 2021 found 1,378 denosumab-associated ONJ reports at the 60 mg dose, with a reporting rate roughly comparable to oral nitrogen-containing bisphosphonates at standard osteoporosis doses. [8] Dental procedures involving bone, poor oral hygiene, and concurrent corticosteroid use are the primary modifying risk factors.

Atypical Femur Fractures

Atypical femur fractures (AFFs) have been reported with long-term denosumab use, though the absolute risk remains low. The 2016 ASBMR Task Force report confirmed AFF cases associated with denosumab, generally after 4 or more years of continuous therapy. [9] The mechanism parallels bisphosphonate-associated AFFs: prolonged suppression of bone turnover may impair microdamage repair in cortical bone. Prodromal thigh pain warrants imaging. If an incomplete fracture is found on the lateral femoral cortex, orthopedic review is indicated before prophylactic nailing is chosen over medication adjustment.

Serious Infections

The package insert for Prolia carries a warning for serious infections, including skin infections (predominantly cellulitis), urinary tract infections, and endocarditis. In the FREEDOM trial (N=7,808), the serious infection rate was 4.1% in the denosumab arm versus 3.4% in placebo over 36 months, a difference that did not reach statistical significance at P=0.12. [10] Post-market case reports, however, have identified rare but severe opportunistic infections in immunocompromised patients, and the drug is generally avoided in patients with active infections.

Dermatologic Reactions

Dermatitis, eczema, and rash occur in roughly 11% of patients in clinical trials, versus 8% on placebo. [10] These reactions are generally mild. Severe hypersensitivity, including anaphylaxis, is listed in the prescribing information as a rare possibility.

What Every Clinician Should Know About Discontinuation Planning

The ASBMR 2022 Task Force on secondary fracture prevention states explicitly: "Denosumab should not be discontinued without a plan to transition to alternative antiresorptive therapy." [11] That sentence carries regulatory and medicolegal weight. Stopping denosumab without bridging is now viewed in many malpractice contexts the same way as stopping anticoagulation in a patient with a mechanical heart valve without a plan.

Bisphosphonate Bridging After Denosumab

The standard transition protocol involves starting a bisphosphonate 4 to 5 months after the last denosumab injection, timed to coincide with the anticipated CTX rebound. Options include:

• Zoledronic acid (Reclast) 5 mg IV, single infusion, given at month 4 to 5 post-last Prolia dose. This is the preferred approach for patients with poor oral absorption or adherence concerns.
• Alendronate 70 mg oral weekly, started at month 4 to 5, continued for at least 12 months.

A 2020 randomized trial by Freemantle et al. Found that a single dose of zoledronic acid given 6 months after the last denosumab injection preserved lumbar spine BMD at 24 months post-denosumab in 83% of patients, compared to 41% in the non-bridged group. [12] The trial used CTX as a pharmacodynamic guide. Patients whose CTX had not risen above 0.30 ng/mL at the time of zoledronic infusion showed better BMD preservation than those with higher CTX, suggesting that earlier administration may be more protective.

When the Patient Has Already Missed an Injection

A missed injection is a clinical emergency that requires same-day management, not rescheduling. The clinician should:

1. Confirm the date of the last injection from pharmacy records.
2. Order serum CTX and P1NP immediately. Elevated CTX indicates the rebound has already started.
3. If the last injection was more than 5 months ago, start bridging with alendronate 70 mg weekly while arranging the next Prolia dose or transitioning off entirely.
4. Obtain a lateral spine X-ray or VFA (vertebral fracture assessment) with DXA if the patient reports back pain or height loss. Fractures can occur silently.
5. Discuss goals of therapy with the patient. If denosumab is being continued, give the injection as soon as possible. If stopping permanently, proceed with formal bisphosphonate bridging.

Duration of Bridging Therapy

How long to continue bridging bisphosphonate therapy after denosumab discontinuation is not fully settled by randomized data, but ASBMR task force consensus and observational data support at least 12 months of oral bisphosphonate or a single IV zoledronic acid dose followed by monitoring. [11] In patients with very low BMD (T-score below -3.0) or prior fractures, longer bisphosphonate courses or transition to romosozumab or teriparatide may be appropriate before a bisphosphonate is used alone.

Bone Turnover Markers as a Safety Net

Serum CTX (C-terminal telopeptide of type I collagen) is the single most useful biochemical tool for managing denosumab discontinuation. Normal pre-menopausal reference range is below 0.30 ng/mL. During denosumab therapy, CTX is typically suppressed below 0.10 ng/mL. After the last injection, a CTX rise above 0.30 ng/mL signals that resorption has rebounded above baseline and fracture risk is accumulating rapidly. [3]

P1NP (procollagen type I N-terminal propeptide) reflects bone formation and rises more slowly during the rebound than CTX. Clinicians who monitor both markers get a fuller picture of the uncoupling dynamic: resorption rises first and sharply; formation follows weeks later, but not fast enough to offset the resorption-driven bone loss.

A reasonable monitoring schedule after the last denosumab dose:

• Month 3: serum CTX and P1NP, calcium, 25-OH vitamin D
• Month 5: repeat CTX. If above 0.30 ng/mL and bisphosphonate has not yet been started, initiate immediately.
• Month 12: DXA to confirm BMD trajectory
• Month 24: repeat DXA and markers to assess bridging adequacy

Special Populations

Men on Androgen Deprivation Therapy

Denosumab 60 mg every 6 months is FDA-approved to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT). In this population, the rebound risk on discontinuation is equally real. ADT itself is profoundly bone-destructive, and men stopping denosumab while still on ADT face a dual threat. A 2020 case series in the Journal of Urology documented three men who developed multiple vertebral fractures within 9 months of stopping denosumab without bridging while remaining on ADT. [13]

Patients With Chronic Kidney Disease

Denosumab does not require dose adjustment for renal impairment, unlike bisphosphonates, which are contraindicated or require caution at GFR below 35 mL/min/1.73 m². That makes denosumab attractive in stage 3 to 4 CKD. The withdrawal problem, however, is amplified in this group because bisphosphonate bridging options are limited when GFR falls below 35. For CKD patients stopping denosumab, the transition plan requires a nephrologist and endocrinologist collaborating, with close attention to calcium, phosphorus, and parathyroid hormone. [7]

Patients Who Received Denosumab for Fewer Than 2 Years

Short-duration use (1 to 2 years) carries a lower but still real rebound risk. Some clinicians have argued that bridging may not be necessary after only 2 injections, but published MVF cases after short-course denosumab exist. The 2022 ASBMR guidance does not carve out any duration below which bridging can be omitted. [11] Caution is warranted regardless of treatment duration.

Rare and Emerging Adverse Events

Beyond the well-established risks, several rare adverse events continue to surface in post-market data.

Hypersensitivity and Anaphylaxis

Anaphylaxis is listed in the current prescribing information. [6] FAERS data through 2023 include 87 reports of anaphylaxis or anaphylactic shock associated with the 60 mg osteoporosis indication. Most reactions occurred at or within 30 minutes of the injection. Clinics administering Prolia should have epinephrine available and observe patients for at least 15 minutes post-injection.

New or Worsening Inflammatory Arthritis

Post-market reports describe flares of rheumatoid arthritis and psoriatic arthritis in patients starting denosumab, though causality is difficult to establish given that these conditions are common in the osteoporosis age group. The RANKL pathway has immunomodulatory roles beyond bone, and its suppression may shift synovial cytokine profiles in susceptible individuals.

Cardiovascular Events

Large trial data from FREEDOM (N=7,808, 36 months) and the FREEDOM Extension (10 years) do not show a statistically significant increase in cardiovascular events with denosumab. [10] A pharmacoepidemiologic cohort study published in BMJ Open (2022, N=24,800) found no elevated risk of myocardial infarction or stroke compared with alendronate. [14] This signal is considered resolved by current evidence, but monitoring continues through post-market studies.

Patient Communication Points

Patients frequently receive inadequate counseling about what happens when Prolia is stopped. Key messages every prescriber should deliver at each visit:

1. Prolia is not a drug you can simply stop. Missing an injection is not the same as taking a break.
2. If you move, change insurance, or lose access to the drug, call the office the same day. Do not wait until the next scheduled appointment.
3. Back pain after stopping Prolia requires evaluation the same week, not reassurance and watchful waiting.
4. The goal is not to be on Prolia forever. Every 2 to 3 years, the prescriber should reassess fracture risk and discuss whether to continue, switch, or plan a formal transition.

The Endocrine Society Clinical Practice Guideline on osteoporosis (2019) states: "Because of the risk of multiple vertebral fractures after denosumab discontinuation, patients should be counseled to not discontinue denosumab without first consulting their physician." [15]

HealthRX Denosumab Discontinuation Decision Framework

The following framework was developed by the HealthRX medical team for use by telemedicine prescribers managing patients who present having already missed a Prolia injection or who want to stop.

Step 1: Classify the situation

• Planned discontinuation (patient and prescriber agree to stop) vs. Unplanned (missed injection, insurance lapse, access problem).

Step 2: Determine time since last injection

• Less than 5 months: give the next injection on schedule or as soon as possible if delayed. No bridging needed yet.
• 5 to 7 months: high urgency. Order CTX immediately. Start alendronate 70 mg weekly while arranging evaluation.
• More than 7 months: treat as active rebound. Start bridging same day. Order lateral spine X-ray and DXA with VFA. Refer to endocrinology or metabolic bone disease specialist.

Step 3: Assess fracture risk tier

• High risk (T-score below -2.5, prior vertebral fracture, or age above 75): prefer zoledronic acid IV as bridge. Single 5 mg infusion at month 4 to 5 post-last dose.
• Moderate risk (T-score -1.5 to -2.5, no prior fracture): alendronate 70 mg weekly for 12 months is acceptable.

Step 4: Monitor and confirm

• Repeat CTX at month 3 and 6 of bridging. If CTX remains above 0.30 ng/mL on oral alendronate, consider escalating to zoledronic acid.
• Repeat DXA at 12 months post-last denosumab dose.

Step 5: Long-term plan

• If BMD has stabilized and FRAX 10-year major fracture risk is below 10%, discuss stopping the bisphosphonate bridge after 12 to 18 months with annual monitoring.
• If BMD has not stabilized or FRAX risk remains high, continue bisphosphonate or consider romosozumab.